Atlas Trials

Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy

Clinical trial NCT02178475 · COMPLETED

Trial details

NCT number
NCT02178475
Sponsor
Amgen
Status
COMPLETED
Study type
OBSERVATIONAL
Chemotherapy-induced Febrile Neutropenia
Start date
2014-07-18
Primary completion
2016-10-28
Enrollment
943

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.